Combinatory Treatment with MiR-7-5p and Drug-Loaded Cubosomes Effectively Impairs Cancer Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Jul 26

PMID 32708846

Citations 24

Authors

Ewa Gajda

Marlena Godlewska

Zenon Mariak

Ewa Nazaruk

Damian Gawel

Affiliations

Soon will be listed here.

Abstract

Background: Multidrug resistance (MDR) is an emerging problem in the treatment of cancer. Therefore, there is a necessity for novel strategies that would sensitize tumor cells to the administered chemotherapeutics. One of the innovative approaches in fighting drug-resistant tumors is the treatment of cancer with microRNA (miRNA), or the use of cubosomes (lipid nanoparticles) loaded with drugs. Here, we present a study on a novel approach, which combines both tools.

Methods: Cubosomes loaded with miR-7-5p and chemotherapeutics were developed. The effects of drug- and miRNA-loaded vehicles on glioma- (A172, T98G), papillary thyroid- (TPC-1) and cervical carcinoma-derived (HeLa) cells were analyzed using molecular biology techniques, including quantitative real-time PCR, MTS-based cell proliferation test, flow cytometry and spheroids formation assay.

Results: The obtained data indicate that miR-7-5p increases the sensitivity of the tested cells to the drug, and that nanoparticles loaded with both miRNA and the drug produce a greater anti-tumor effect in comparison to the free drug treatment. It was found that an increased level of apoptosis in the drug/miRNA co-treated cells is accompanied by an alternation in the expression of the genes encoding for key MDR proteins of the ABC family.

Conclusions: Overall, co-administration of miR-7-5p with a chemotherapeutic can be considered a promising strategy, leading to reduced MDR and the induction of apoptosis in cancer cells.

Citing Articles

Environmental Exposure to Bisphenol A Enhances Invasiveness in Papillary Thyroid Cancer.

Huang C, Xie R, Li P, Chen C, You B, Sun Y Int J Mol Sci. 2025; 26(2).

PMID: 39859529 PMC: 11766120. DOI: 10.3390/ijms26020814.

MiRNAs: main players of cancer drug resistance target ABC transporters.

Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39808313 DOI: 10.1007/s00210-024-03719-y.

Enhancement of Temozolomide Stability and Anticancer Efficacy by Loading in Monopalmitolein-Based Cubic Phase Nanoparticles.

Nazaruk E, Gajda E, Ziedalska I, Godlewska M, Gawel D ACS Omega. 2024; 9(37):38936-38945.

PMID: 39310207 PMC: 11411539. DOI: 10.1021/acsomega.4c05291.

Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment.

Gawel A, Betkowska A, Gajda E, Godlewska M, Gawel D Biomedicines. 2024; 12(8).

PMID: 39200286 PMC: 11351974. DOI: 10.3390/biomedicines12081822.

Role of Non-coding RNAs in the Response of Glioblastoma to Temozolomide.

Goleij P, Pourali G, Raisi A, Ravaei F, Golestan S, Abed A Mol Neurobiol. 2024; 62(2):1726-1755.

PMID: 39023794 DOI: 10.1007/s12035-024-04316-z.

References

Zhao N, Woodle M, Mixson A . Advances in delivery systems for doxorubicin. J Nanomed Nanotechnol. 2019; 9(5). PMC: 6319900. DOI: 10.4172/2157-7439.1000519. View

Horsham J, Ganda C, Kalinowski F, Brown R, Epis M, Leedman P . MicroRNA-7: A miRNA with expanding roles in development and disease. Int J Biochem Cell Biol. 2015; 69:215-24. DOI: 10.1016/j.biocel.2015.11.001. View

Sadeghi-Aliabadi H, Minaiyan M, Dabestan A . Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci. 2011; 5(2):127-33. PMC: 3203264. View

Gandhi N, Tekade R, Chougule M . Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release. 2014; 194:238-56. PMC: 4254052. DOI: 10.1016/j.jconrel.2014.09.001. View

Costa P, Cardoso A, Custodia C, Cunha P, de Almeida L, de Lima M . MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. J Control Release. 2015; 207:31-9. DOI: 10.1016/j.jconrel.2015.04.002. View

Jia B, Liu W, Gu J, Wang J, Lv W, Zhang W . MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. Exp Cell Res. 2018; 375(1):73-81. DOI: 10.1016/j.yexcr.2018.12.016. View

Bouzinab K, Summers H, Zhang J, Stevens M, Moody C, Turyanska L . In search of effective therapies to overcome resistance to Temozolomide in brain tumours. Cancer Drug Resist. 2022; 2(4):1018-1031. PMC: 9019207. DOI: 10.20517/cdr.2019.64. View

Yin C, Kong W, Jiang J, Xu H, Zhao W . miR-7-5p inhibits cell migration and invasion in glioblastoma through targeting SATB1. Oncol Lett. 2019; 17(2):1819-1825. PMC: 6341908. DOI: 10.3892/ol.2018.9777. View

Duan Y, Zhang Y, Peng W, Jiang P, Deng Z, Wu C . and 51 as diagnostic biomarkers for papillary thyroid carcinoma in formalin-fixed paraffin-embedded tissues. Pharmazie. 2020; 75(6):266-270. DOI: 10.1691/ph.2020.0335. View

10.

Taratula O, Garbuzenko O, Chen A, Minko T . Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 2011; 19(10):900-14. DOI: 10.3109/1061186X.2011.622404. View

11.

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N . Drug resistance in cancer: an overview. Cancers (Basel). 2014; 6(3):1769-92. PMC: 4190567. DOI: 10.3390/cancers6031769. View

12.

Allen K, Weiss G . Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 2010; 9(12):3126-36. DOI: 10.1158/1535-7163.MCT-10-0397. View

13.

Shergalis A, Bankhead 3rd A, Luesakul U, Muangsin N, Neamati N . Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol Rev. 2018; 70(3):412-445. PMC: 5907910. DOI: 10.1124/pr.117.014944. View

14.

Bertucci A, Prasetyanto E, Septiadi D, Manicardi A, Brognara E, Gambari R . Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. Small. 2015; 11(42):5687-95. DOI: 10.1002/smll.201500540. View

15.

Medarova Z, Pantazopoulos P, Yoo B . Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells. Sci Rep. 2020; 10(1):1970. PMC: 7005303. DOI: 10.1038/s41598-020-58919-2. View

16.

Nazaruk E, Majkowska-Pilip A, Bilewicz R . Lipidic Cubic-Phase Nanoparticles-Cubosomes for Efficient Drug Delivery to Cancer Cells. Chempluschem. 2020; 82(4):570-575. DOI: 10.1002/cplu.201600534. View

17.

Chen X, Zhang M, Gan H, Wang H, Lee J, Fang D . A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018; 9(1):2949. PMC: 6063898. DOI: 10.1038/s41467-018-05373-4. View

18.

Liu Z, Liu Y, Li L, Xu Z, Bi B, Wang Y . MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1. Tumour Biol. 2014; 35(10):10177-84. DOI: 10.1007/s13277-014-2318-x. View

19.

Guo J, Xu L, Teng X, Sun M . MicroRNA-7-5p regulates the proliferation and migration of intestinal epithelial cells by targeting trefoil factor 3 via inhibiting the phosphoinositide 3-kinase/Akt signalling pathway. Int J Mol Med. 2017; 40(5):1435-1443. PMC: 5627888. DOI: 10.3892/ijmm.2017.3120. View

20.

Chen Y, Ma P, Gui S . Cubic and hexagonal liquid crystals as drug delivery systems. Biomed Res Int. 2014; 2014:815981. PMC: 4068036. DOI: 10.1155/2014/815981. View